PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
NCT ID: NCT05573893
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
800 participants
OBSERVATIONAL
2023-09-12
2031-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All diagnostic and treatment procedures including visit frequency are at the discretion of the treating physician and not defined by the protocol. T-DXd treatment is considered as a selection criteria. Patients will be informed about use of digital healthcare application (DiGA).
Approximately 800 eligible participants will be enrolled which includes 400 patients in the HER2-positive cohort and 400 patients in the HER2-low/ HER2-ultralow cohort.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Cohort 1 containing patients with documented HER2-positive unresectable or metastatic BC receiving T-DXd treatment in line with the applicable summary of product characteristics (SmPC) within routine clinical practice.
No interventions assigned to this group
Cohort 2
Cohort 2 containing patients with documented HER2-low or HER2-ultralow unresectable or metastatic BC receiving T-DXd treatment in line with the applicable summary of product characteristics (SmPC) within routine clinical practice.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients (irrespective of sex and gender) with pathologically documented breast cancer that:
* is unresectable or metastatic
* has confirmed HER2+, HER2-low or HER2-ultralow tumor status by local pathology
* was previously treated with one or more anti-HER2 directed therapy if the tumor is HER2+ OR
* was previously treated with at least one endocrine therapy in the metastatic setting and is not considered suitable for endocrine therapy as the next line of treatment if the tumor is HR+, HER2-low or HER2-ultralow OR
* was previously treated with prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy if the tumor is HER2-low.
3. Has documented radiologic progression (during or after most recent treatment)
4. Patient is eligible for T-DXd treatment in line with the specifications mentioned in the ENHERTU® SmPC and is scheduled for T-DXd treatment \*
5. Patient is able to read and understand either German or English
6. Signed written informed consent
* The prescription of the medicinal product is clearly separated from the decision to include the patient in this NIS.
Exclusion Criteria
2. Known hypersensitivity to T-DXd or any of the excipients of the drug
3. Pregnancy or breast feeding
4. Current or planned participation in an interventional clinical trial
5. Current or planned systemic treatment of any tumor other than unresectable or metastatic BC
Patients who have never received any T-DXd dose will be discontinued from the study and will be considered as a late screening failure, no further documentation besides reason and date of discontinuation is needed.
18 Years
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daiichi Sankyo
INDUSTRY
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Amberg, , Germany
Research Site
Ansbach, , Germany
Research Site
Apolda, , Germany
Research Site
Aschaffenburg, , Germany
Research Site
Augsburg, , Germany
Research Site
Augsburg, , Germany
Research Site
Bad Reichenhall, , Germany
Research Site
Baden-Baden, , Germany
Research Site
Balingen, , Germany
Research Site
Bamberg, , Germany
Research Site
Berlin, , Germany
Research Site
Berlin, , Germany
Research Site
Berlin, , Germany
Research Site
Berlin, , Germany
Research Site
Bielefeld, , Germany
Research Site
Bonn, , Germany
Research Site
Brandenburg, , Germany
Research Site
Braunschweig, , Germany
Research Site
Bremen, , Germany
Research Site
Bremerhaven, , Germany
Research Site
Coburg, , Germany
Research Site
Dessau, , Germany
Research Site
Donauwörth, , Germany
Research Site
Dortmund, , Germany
Research Site
Dresden, , Germany
Research Site
Dresden, , Germany
Research Site
Düsseldorf, , Germany
Research Site
Eggenfelden, , Germany
Research Site
Erfurt, , Germany
Research Site
Essen, , Germany
Research Site
Filderstadt - Bonlanden, , Germany
Research Site
Frankfurt, , Germany
Research Site
Freudenstadt, , Germany
Research Site
Fürstenfeldbruck, , Germany
Research Site
Fürstenwalde, , Germany
Research Site
Gerlingen, , Germany
Research Site
Giessen, , Germany
Research Site
Halle, , Germany
Research Site
Hamburg, , Germany
Research Site
Hamburg, , Germany
Research Site
Hanover, , Germany
Research Site
Hanover, , Germany
Research Site
Heidenheim, , Germany
Research Site
Heilbronn, , Germany
Research Site
Hildesheim, , Germany
Research Site
Homburg/Saar, , Germany
Research Site
Jena, , Germany
Research Site
Kaiserslautern, , Germany
Research Site
Karlsruhe, , Germany
Research Site
Kassel, , Germany
Research Site
Kassel, , Germany
Research Site
Kempten, , Germany
Research Site
Kiel, , Germany
Research Site
Kulmbach, , Germany
Research Site
Landshut, , Germany
Research Site
Leer, , Germany
Research Site
Leipzig, , Germany
Research Site
Loerrach, , Germany
Research Site
Lübeck, , Germany
Research Site
Lüneburg, , Germany
Research Site
Magdeburg, , Germany
Research Site
Mainz, , Germany
Research Site
Marburg, , Germany
Research Site
Memmingen, , Germany
Research Site
Mönchengladbach, , Germany
Research Site
Mutlangen, , Germany
Research Site
Mühlhausen, , Germany
Research Site
München, , Germany
Research Site
München, , Germany
Research Site
München, , Germany
Research Site
Neumarkt, , Germany
Research Site
Neustadt am Rübenberge, , Germany
Research Site
Nordhausen, , Germany
Research Site
Nuremberg, , Germany
Research Site
Oldenburg, , Germany
Research Site
Oranienburg, , Germany
Research Site
Potsdam, , Germany
Research Site
Recklinghausen, , Germany
Research Site
Regensburg, , Germany
Research Site
Rosenheim, , Germany
Research Site
Rotenburg (Wümme), , Germany
Research Site
Saalfeld, , Germany
Research Site
Saarbrücken, , Germany
Research Site
Salzwedel, , Germany
Research Site
Schwäbisch Hall, , Germany
Research Site
Siegen, , Germany
Research Site
Singen, , Germany
Research Site
Solingen, , Germany
Research Site
Stade, , Germany
Research Site
Stuttgart, , Germany
Research Site
Torgau, , Germany
Research Site
Troisdorf, , Germany
Research Site
Ulm, , Germany
Research Site
Walsrode, , Germany
Research Site
Weiden, , Germany
Research Site
Weinheim, , Germany
Research Site
Weisenfels, , Germany
Research Site
Westerstede, , Germany
Research Site
Wiesbaden, , Germany
Research Site
Winnenden, , Germany
Research Site
Wolfsburg, , Germany
Research Site
Wuppertal, , Germany
Research Site
Würzburg, , Germany
Research Site
Zittau, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
AstraZeneca Clinical Study Information Center
Role: CONTACT
Phone: 1-877-240-9479
Email: [email protected]
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D9673R00028
Identifier Type: -
Identifier Source: org_study_id